Reason for request
Extension of the indication
Clinical Benefit
Clinical Added Value
| moderate |
Given the efficacy of VOTUBIA (everolimus) in reducing renal angiomyolipoma volume associated with tuberous sclerosis complex in adult patients, VOTUBIA provides a substantial improvement in actual benefit (IAB III) in the treatment of patients not requiring immediate surgery (nephrectomy or embolisation). |
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
wN3g5HKEEqYXSXWJ
